MedPath

Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

Phase 3
Recruiting
Conditions
Neuroprotection
Congenital Heart Disease in Children
Interventions
Registration Number
NCT04217421
Lead Sponsor
dr. M.J.N.L. Benders
Brief Summary

Neurodevelopmental impairment due to delayed brain development and brain injury is a fundamental problem in children with critical congenital heart disease (CCHD). Significant longterm motor-, cognitive-, and behavioral problems are the result of early postnatally and perioperatively induced brain injury. Allopurinol, a xanthine oxidase inhibitor, prevents the formation of toxic free oxygen radicals, thereby limiting hypoxia-reperfusion damage. Both animal and neonatal studies suggest that administration of allopurinol reduces hypoxic-ischemic brain injury, is cardioprotective, and safe. This study aims to evaluate the efficacy and safety of allopurinol administered early postnatally and perioperatively in children with a CCHD requiring cardiac surgery with cardiopulmonary bypass.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
236
Inclusion Criteria
  • Neonates with a prenatally or postnatally confirmed diagnosis of CCHD requiring (anticipated) cardiac surgery with CPB within the first 4 weeks of life.
  • Informed consent provided by both parents.
Exclusion Criteria
  • Inability to enroll the patient before the start of delivery in case of prenatal diagnosis, or 24 hours before surgery in case of postnatal diagnosis.
  • Doubt whether the aortic arch anomaly before birth requires cardiac surgery with CPB in the neonatal period.
  • Gestational age below 36 weeks and/or birth weight less than 2000 gram.
  • Surgery not requiring cardiopulmonary bypass.
  • Decision for "comfort care only".

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AllopurinolAllopurinol-
PlaceboMannitol-
Primary Outcome Measures
NameTimeMethod
Incidence of mortalitybetween birth and 1 month after cardiac surgery

Defined as death until one month postoperatively.

Rate of children that are considered 'too unstable for postoperative MRI'between birth and 1 month after cardiac surgery

This decision is based on the circulatory and respiratory status of the child before the planned postoperative MRI, as included in local guidelines (not part of this protocol) of each participating center.

Relevant parenchymatous brain injury on postoperative MRIbetween birth and 1 month after cardiac surgery

The presence or absence of relevant (moderate/severe) parenchymatous (ischemic or hemorrhagic) brain injury on postoperative MRI will be assessed, using the T1/T2/DWI and SWI weighted images.

Secondary Outcome Measures
NameTimeMethod
Brain injury severity score on pre- and postoperative MRIbetween birth and 1 month after cardiac surgery

An MRI score, which includes diffusion-weighted imaging as well as assessment of the deep grey matter, white matter, and cerebellum \[Weeke L, et al. J Pediatr 2018\]. The score will be compared between groups (allopurinol vs placebo).

Global ventricular function (normal, mildly, moderately, severely, reduced) pre- and postoperativelybetween birth and 1 month after cardiac surgery
Ventricular ejection fraction (%) pre- and postoperativelybetween birth and 1 month after cardiac surgery
Brain function: Seizure activity on aEEG (presence or absence) postnatally and postoperatively24-36 hours after birth, 6 hours before surgery, 48-72 hours after surgery
Neurodevelopmentat 24 months

To assess motor, cognitive, speech and language development using the Bayley Scales of Infant and Toddler Development - Third Edition - NL (Bayley-III-NL). An average Bayley-III-NL score is 100, one standard deviation (SD) above or below the mean concerns 15 points. Scores will be compared between groups (allopurinol vs placebo).

Quality of Life (scores and subscores): TNO-AZL TAPQoLat 24 months

The TNO-AZL Questionnaire for Preschool Children's Health-Related Quality of Life (TAPQoL) will be assessed to give insight in the quality of life of both children with CCHD and their parents. A higher score indicates a better quality of life. Scores will be compared between groups (allopurinol vs placebo).

Brain oxygenation: Regional cerebral oxygen saturation (%) postnatally and postoperatively24-36 hours after birth, 6 hours before surgery, 48-72 hours after surgery
Volume of hypoxic-ischemic brain injury on pre- and postoperative MRIbetween birth and 1 month after cardiac surgery

To assess whether there are differences between groups (allopurinol vs placebo) in volume (mm3) of hypoxic-ischemic brain lesions using a fully automatic method for detection and quantification of ischemic lesions in diffusion-weighted MR images \[Murphy K, et al. Neuroimage Clin 2017\].

General movements and motor optimality scoreat 3 months

Video recordings will be analyzed following the global general movement categories (normal, poor repertoire, cramped-synchronized, or chaotic) and the motor optimality score \[Einspieler C, et al. Dev Med Child Neurol. 2016\]. A higher score expresses a more optimal performance. Scores will be compared between groups (allopurinol vs placebo).

Trial Locations

Locations (4)

University Medical Center Groningen (UMCG)

🇳🇱

Groningen, Netherlands

Radboud University Medical Center Nijmegen (Radboudumc)

🇳🇱

Nijmegen, Netherlands

Erasmus Medical Center Rotterdam (Erasmus MC)

🇳🇱

Rotterdam, Netherlands

University Medical Center Utrecht (UMC Utrecht)

🇳🇱

Utrecht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath